drugset
drugset / Trial / NCT05199493

Reducing Acute Kidney Injury Occurence by Administering Angiotensin II

NCT05199493 ↗

Phase 3 Completed 64 enrolled University of Münster German Research Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to evaluate whether adding angiotensin II to the standard of care is superior compared to the standard of care alone with respect to kidney damage (personalized approach) after cardiac surgery.

Timeline

Start
2021-12-27
Primary completion
2022-12-19
Completion
2023-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Angiotensin II Peptide — Intravenous

Indications

cardiac valvular defect vascular disorder